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ABSTRACT
Human amniotic fluid stem cells (hAFS) have shown a distinct secretory profile and significant
regenerative potential in several preclinical models of disease. Nevertheless, little is known about
the detailed characterization of their secretome. Herein we show for the first time that hAFS
actively release extracellular vesicles (EV) endowed with significant paracrine potential and regen-
erative effect. c-KIT1 hAFS were isolated from leftover samples of amniotic fluid from prenatal
screening and stimulated to enhance EV release (24 hours 20% O2 versus 1% O2 preconditioning).
The capacity of the c-KIT1 hAFS-derived EV (hAFS-EV) to induce proliferation, survival, immunomo-
dulation, and angiogenesis were investigated in vitro and in vivo. The hAFS-EV regenerative poten-
tial was also assessed in a model of skeletal muscle atrophy (HSA-Cre, SmnF7/F7 mice), in which
mouse AFS transplantation was previously shown to enhance muscle strength and survival. hAFS
secreted EV ranged from 50 up to 1,000 nm in size. In vitro analysis defined their role as biological
mediators of regenerative, paracrine effects while their modulatory role in decreasing skeletal
muscle inflammation in vivo was shown for the first time. Hypoxic preconditioning significantly
induced the enrichment of exosomes endowed with regenerative microRNAs within the hAFS-EV.
In conclusion, this is the first study showing that c-KIT1 hAFS dynamically release EV endowed
with remarkable paracrine potential, thus representing an appealing tool for future regenerative
therapy. STEM CELLS TRANSLATIONAL MEDICINE 2017;6:1340–1355
SIGNIFICANCE STATEMENT
This is the first study providing a first characterization of the human amniotic fluid stem cell
(hAFS)-derived extracellular vesicles (EV). hAFS are fetal mesenchymal progenitors with a dis-
tinct cardioprotective and angiogeneic secretory profile that can be easily isolated, expanded,
and cryopreserved, hence representing a suitable candidate for future clinical applications. Stem
cell-secreted EV are mediators of intercellular communication and have been described as
active components of paracrine regenerative effects. Here we showed that EV from hAFS medi-
ate significant prosurvival, proliferative, and anti-inflammatory effects and may represent an
ideal approach for next generation therapy. Therefore, AFS might be exploited as “drug-stores”
to produce EV endowed with paracrine regenerative potential that could ultimately be har-
nessed as advanced medicinal product.
INTRODUCTION
Stem cell-derived paracrine effects have emerged
as promising strategy for the reactivation of
endogenous mechanisms of repair and regenera-
tion in several disease models [1–3]. Mounting
evidence has shown that transplanted stem cells
can release trophic signals that influence the
microenvironment. This has led to a significant
shift in paradigms, from exploring the stem cell
genome to analyzing the stem cell “secretome,”
the latter of which includes the entirely of growth
factors and chemoattractant molecules produced
by stem cells. In this scenario, growing interest
has focused on the characterization of stem cell-
secreted extracellular vesicles (EV). EV are
membrane-bound cellular components enriched
with soluble, bioactive factors (proteins, lipids,
etc.) and RNA (mainly regulatory microRNA—
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mediating horizontal intercellular transfer of genetic information
on the responder cell, consequently modulating its function. EV
are secreted as microsized (microvesicles: 100–1,000 nm) and
nanosized (exosomes: 30–150 nm) particles, thus acting as key
biological effectors of paracrine signaling [4]. Microvesicles are
released as shedding vesicles by direct budding of the plasma
membrane, while exosomes are produced in endosomal multive-
sicular compartments (multivesicular body, MVB) and secreted as
the MVB fuses with the plasma membrane [5]. Recent studies
have shown that the beneficial effects observed following stem
cell transplantation in several preclinical models of experimental
ischemic disease and injury could be mediated by stem cell-EV.
These include the activation of antiapoptotic and prosurvival path-
ways eliciting angiogenic, anti-inflammatory, and antifibrotic
responses, and the stimulation of resident endogenous progeni-
tors, overall enhancing organ function [6]. In particular, many
studies have reported the potential efficacy of EV from adult mes-
enchymal stem cells (MSC) in providing cardioprotection against
acute myocardial infarction (MI) [7–9], in enhancing wound heal-
ing [10], counteracting graft-versus-host-disease [11], reducing
renal injury [12], mediating liver regeneration [13] and stimulating
neural plasticity following stroke [14]. Since cell-free delivery of
bioactive cargos by EV recapitulates the same beneficial
responses of stem cell transplantation, they offer remarkable
benefits over conventional cell therapy as immunologically
unresponsive agents [15].
Human amniotic fluid-derived stem cells (hAFS) are broadly
characterized as multipotent mesenchymal progenitors expressing
pluripotency markers and high self-renewal potential similar to
embryonic stem cells, without being tumorigenic or causing any
ethical concern [16]. Because of their fetal, but non-embryonic
origin, hAFS overcome many ethical concerns and can be easily
obtained upon the expression of the stem marker c-KIT from left-
over or discarded amniotic fluid samples collected during either
amniocentesis [16, 17] or eligible cesarean delivery [18].We previ-
ously demonstrated that c-KIT1 hAFS exert remarkable cardiopro-
tective paracrine effects reducing the infarct size in a rat acute
model of MI by approximately 14% [19], possibly via the secretion
of the cardioactive peptide thymosin beta 4, which, in turn, can
reactivate epicardial progenitor cells to give rise de novo to fully
mature cardiomyocytes [20]. Moreover, when injected in an
established model of necrotizing enterocolitis, rodent c-KIT1 AFS
have been shown to improve survival and clinical status, while
maintaining the gut structure and function via paracrine modula-
tion of resident stromal cells expressing cyclooxygenase 2 (COX2)
[21]. Similar remarkable results have been also obtained in a
model of skeletal muscle atrophy carrying a homozygous deletion
of the exon 7 within the survival motor neuron (Smn) gene,
specifically directed to new forming skeletal muscle fibers (HSA-
Cre, Smn
F7/F7 mice), where mouse c-KIT1 AFS confirmed their
regenerative potential by providing significant improvement in
muscle strength and in the survival rate of the affected animals,
together with the replenishment of the depleted skeletal muscle
niche [22].
Despite c-KIT1 AFS paracrine potential and distinct proteomic
profile being confirmed by different independent studies [19, 23,
24], at present the functional properties and the role of their
secreted EV (hAFS-EV) have not been elucidated. Consistent with
the observation that hAFS are progenitors with embryonic, stem
cell-like properties, they are likely to possess a powerful paracrine
potential given their early developmental stage. Hence, our
hypothesis is based on the idea that the correlation between the
therapeutic efficacy of the hAFS secretome and their fetal origin
might be underpinned by their EV production and regenerative
potential.
Here we aim to provide a first characterization of the regener-
ative potential of the hAFS-EV, as a new promising tool for a future
cell-free therapy at the frontiers of regenerative medicine.
MATERIALS AND METHODS
Cell Isolation and Culture
hAFS were from leftover samples of amniotic fluid obtained via
amniocentesis upon written informed consent, as previously
described [16, 17]. All procedures were performed in compliance
with the Helsinki Declaration and the local ethical committee
(IRCCS AOU San Martino-IST, P.R. 428REG2015). Normal adult
human dermal fibroblasts (HDF), the mouse myoblast C2C12 cell
line, and primary human peripheral blood mononuclear cells
(hPBMCs) were used for in vitro experiments. For more details,
please refer to Supporting Information.
hAFS Preconditioning
hAFS were cultured for 24 hours in serum-free (SF) medium (Mini-
mum Essential Medium Eagle alpha, with 1% L-glutamine and 1%
penicillin/streptomycin) under normoxic (20% O2 and 5% CO2 at
378C) or hypoxic (1% O2 and 5% CO2 at 378C in a hypoxic incuba-
tor, Eppendorf, Hamburg, Germany; https://www.eppendorf.
com/) conditions. The hAFS-conditioned medium (hAFS-CM) was
collected and processed for hAFS-EV isolation.
Characterization of hAFS After Hypoxic Preconditioning
The expression of specific stem cell markers was assessed by immu-
nostaining using an anti-Stage-Specific Embryonic Antigen-4
(SSEA4) antibody (Abcam, Cambridge, United Kingdom; www.
abcam.com) and an anti-NANOG antibody (Epitomics, Cambridge,
United Kingdom). NANOG mRNA levels were also evaluated by
both qualitative reverse transcription-polymerase chain reaction
(RT-PCR) and real time qRT-PCR. hAFS protein content was analyzed
by Western Blot (WB) for human hypoxia inducible factor-1 alpha
(HIF-1a BD Bioscience, East Rutherford, New Jersey, http://www.
bdbiosciences.com/eu/solrSearch?text=hypoxia+1+alpha&x=0&y=0)
and bACTIN (Santa Cruz Biotechnology, Dallas, Texas, https://www.
scbt.com/scbt/home?&_requestid=235153). hAFS immunopheno-
type and viability was assessed by fuorescence-activated cell sorting
(FACS). For more details, refer to Supporting Information.
Isolation and Characterization of hAFS-EV
A scheme of hAFS-EV isolation is shown in Supporting Information
Figure S1. hAFS-EV were isolated by ultracentrifugation [5] from
hAFS-CM obtained from cells cultured for 24 hours under SF nor-
moxic (hAFS-CMNormo) or hypoxic (hAFS-CMHypo) conditions. hAFS
and hAFS-EV were analyzed by transmission electron microscopy
(TEM). hAFS-EV were characterized by nanoparticle tracking tech-
nology using a NanoSight LM10 (Malvern Instruments, Malvern,
United Kingdom, http://www.malvern.com/en/?gclid=CJ746Zr-
K9NECFcMy0wodhJwFxA) to analyze particles released by 106
cells. The concentration of membrane-bound protein on the sur-
face of freshly isolated, intact hAFS-EV was measured using BiCin-
choninic acid (BCA) assay (Thermo Fisher Scientific, Waltham,
Massachusetts, http://www.thermofisher.com/it/en/home.html).
Balbi, Piccoli, Barile et al. 1341
Oc 2017 The Authors STEM CELLS TRANSLATIONAL MEDICINE published by
Wiley Periodicals, Inc. on behalf of AlphaMed Press
STEM CELLS TRANSLATIONAL MEDICINE
WB on hAFS and hAFS-EV was performed for the expression of
TSG101 (Abcam, Cambridge, United Kingdom, http://www.abcam.
com), ALIX (Santa Cruz Biotechnology, Dallas, Texas, https://www.
scbt.com/scbt/home?&_requestid=235153), GRP94 (Abcam, Cam-
bridge, United Kingdom; www.abcam.com), and human bACTIN
(Santa Cruz Biotechnlology, Dallas, Texas, https://www.scbt.com/
scbt/home?&_requestid=235153). hAFS-EV were also evaluated by
FACS for the presence on their surface of the MSC antigen CD105
(eBioscience, Waltham, Massachusetts, https://www.ebioscience.
com/), the conventional exosomal markers CD81, CD9, CD63,
Annexin V (AnnV), and the costimulatory molecules CD80 and
CD86 (all BD Bioscience, East Rutherford, New Jersey, https://
www.ebioscience.com/). For more details, refer to Supporting
Information.
Uptake Analysis of hAFS-EV by Target Cells and
Functional In Vitro Studies
hAFS-EV were labeled with the PKH67 Green Fluorescent Cell
Linker (Sigma, Milano, Italy, https://www.sigmaaldrich.com/), fol-
lowing manufacturer’s instructions. 1 lg/104 cells (for HDF and
C2C12 cells) and 1 lg/105 cells (for hPBMC) PKH671 hAFS-EVNormo
and PKH671 hAFS-EVHypo were incubated for 3 hours with the tar-
get cells in SF medium. To assess the biological effects driven by
hAFS-EV on HDF and C2C12 cells, three different concentrations (1
lg/104, 2 lg/104, and 4 lg/104 cells) of either hAFS-EVNormo or
hAFS-EVHypo were used. To analyze cell proliferation, HDF
were primed with hAFS-EV and then analyzed by BromodeoxyUri-
dine (BrdU) colorimetric assay (Roche, Basel, Switzerland, http://
www.roche.com/) according to the manufacturer’s instructions.
To define the antiapoptotic effect of hAFS-EV, C2C12 were
incubated with hAFS-EV and exposed to oxidative damage.
Cell viability was measured by 3-(4,5-Dimethylthiazol-2-yl)-2,5-
Diphenyltetrazolium Bromide (MTT) assay using a 150 lg/ml MTT
solution (Sigma-Aldrich, Milano, Italy, https://www.sigmaaldrich.
com/).
Data were acquired on a VersaMax (GE Intelligent Platforms,
Charlottesville, Virginia, https://www.moleculardevices.com/
systems/microplate-readers/absorbance-readers/versamax-elisa-
microplate-reader) plate reader. The immunomodulatory poten-
tial of hAFS-EV was evaluated on hPBMC stimulated with 5 lg/
ml phytohemagglutinin (PHA, Sigma Chemicals Co., Milano, Italy,
https://www.sigmaaldrich.com/) and 5 lg/ml pokeweed mito-
gen (PWM, Sigma Chemicals Co., Milano, Italy, https://www.sig-
maaldrich.com/) for 1 hour, to induce T- and B-lymphocytes
expansion [25, 26], followed by incubation with 1 lg/105 cells of
hAFS-EVNormo or hAFS-EVHypo for 5 days. For more details, refer
to Supporting Information.
In Vivo Angiogenic Matrigel Plug Assay
Adult C57Bl/6J male mice were subcutaneously injected with ice-
cold unpolymerized Matrigel (Corning, New York; https://www.
corning.com/worldwide/en/products/life-sciences/products/surfa-
ces/matrigel-matrix.html) solution containing 10 lg of either
hAFS-EVNormo or hAFS-EVHypo. All the animal work was performed
in compliance with ethical national and international (EU Directive
2010/63/EU) standards and according to institutional guidelines
from the Animal Facility of IRCCS AOU San Martino-IST, Genova.
Mice were sacrificed 3 weeks after injection and Matrigel plugs
were collected for histological and functional evaluation of the
host endothelial infiltrating cells. Real time qRT-PCR was also per-
formed for the expression of VegfA, Pecam1, Cdh5 (VE-Cadherin),
and beta-2-microglobulin (B2M) genes. For more details, refer to
Supporting Information.
Mouse Model of Muscular Atrophy
Twelve-week-old HSA-Cre, SmnF7/F7 mice [22] (n 5 8 per time
point analysis) were randomized to receive either control phos-
phate-buffered saline (PBS) or hAFS-EV, as represented in Figure
5A. One microgram of hAFS-EVNormo and hAFS-EVHypo was injected
in the right and left Tibialis Anterior (TA) muscles, respectively.
Mice were sacrificed 1 and 7 days after treatment and muscle tis-
sue was processed for immunostaining and real time qRT-PCR. All
the animal work was performed in compliance with ethical
national and international (EU Directive 2010/63/EU) standards
according to institutional guidelines from the University of Padova
Animal Care and Use Committee (CEASA, protocol 67/2011). For
more details, refer to Supporting Information.
Small Non-Coding RNA Profiling of hAFS-EV
Total hAFS-EV RNA was extracted using Qiazol Lysis Reagent (QIA-
GEN, Hilden, Germany, http://www.qiagen.com). Analysis of the
small non-coding RNA content was performed on a 2100 Bioana-
lyzer using the Small RNA Kit and the Agilent 2100 expert software
(all from Agilent Technologies, Santa Clara, California, http://www.
agilent.com/home).
Real Time qRT-PCR Analysis of the hAFS-EV microRNA
Content
Total RNA from hAFS and hAFS-EV was extracted using miRNAeasy
Mini Kit following the manufacturer’s instructions. miScript II RT
Kit was used for cDNA synthesis and selected miScript Primer
Assay and miScript SYBRV
R
Green PCR Kits were used for quantita-
tive RT-PCR analysis on a 7500 Fast Real-Time PCR System
(Thermo Fisher Scientific, Waltham, Massachusetts, http://www.
thermofisher.com/it/en/home.html). The following human miR-
NAs (all from QIAGEN, Hilden, Germany; www.qiagen.com) were
evaluated: miR-223, miR-146a, miR-let7c, miR-21, miR-126, miR-
146b, miR-199a-3p, and miR-210. Gene expression levels were
normalized to the corresponding miRNA expression in hAFS using
the 2-ddCt method.
Analysis of Direct Transfer of Exosomal RNA from the
hAFS-EV into Target Cells
RNA content in hAFS-EV was labeled using the SYTOV
R
RNASe-
lectTM Green Fluorescent Nucleic Acid Stain (Thermo Fisher Scien-
tific, Waltham, Massachusetts, http://www.thermofisher.com/it/
en/home.html) following the manufacturer’s instructions. One
microgram of SYTOV
R 1 hAFS-EVNormo or SYTO
VR RNASelect1 hAFS-
EVHypo was incubated for 3 hours with 10
4 HDF or C2C12 cells in
SF medium and analyzed after 1 hour by FACS. For more details,
refer to Supporting Information.
Real time qRT-PCR Evaluation of Specific miRNA
Enrichment and Their Target Genes in the Target Cells
HDF and C2C12 cells were incubated with 4 lg/104 cells of either
hAFS-EVNormo or hAFS-EVHypo in SF medium, following the same
protocol used for cell proliferation and viability assays. After 1
hour incubation in complete medium, total RNA from HDF and
C2C12 cells was isolated using Qiazol Lysis Reagent (QIAGEN, Hil-
den, Germany, www.qiagen.com). Analysis of selected miRNAs
was performed as described above; the miRNA target genes MNT
(HDF) and Casp8ap2 (C2C12) were analyzed by real time qRT-PCR.
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Figure 1. Hypoxic preconditioning does not significantly affect hAFS stemness and phenotype. (A): Bright field, SSEA4 and NANOG immuno-
staining images of hAFS under: (a), (a0), and (a0 0) 24 hours 20% O2 CTRL conditions; (b), (b
0), and (b0 0) 24 hours 20% O2 SF conditions; (c), (c
0),
and (c0 0) 24 hours 1% O2 preconditioning in CTRL medium; (d), (d
0), and (d0 0) 24 hours 1% O2 preconditioning in SF condition; scale bar 50
mm. (B): Western Blot for HIF-1a expression by hAFS after 24 hours of 20% O2 or 1% O2 preconditioning in complete (CTRL) or SF medium.
(C): SSEA41 hAFS under: (a) 24 hours 20% O2 CTRL condition: 87.8%6 2.8%; (b) 24 hours 20%O2 SF condition: 89.9%6 1.5%; (c) 24 hours
1% O2 preconditioning in CTRL medium: 83.0%6 0.7%; and (d) 24 hours 1% O2 preconditioning in SF condition: 84.1%6 2.2%; values
expressed as mean6 SEM. (D): Real time qRT-PCR and qualitative RT-PCR analysis for NANOG and GAPDH expression of hAFS under 24 hours:
(a) 20% O2 CTRL and (b) 20% O2 SF conditions, (c) 1% O2 CTRL and (d) 1% O2 SF conditions; 1ve: positive control, human embryonic stem
cells (****, p< .0001); 2ve: negative control: HDF; n.d. (E): hAFS immunophenotype under 24 hours 20% O2 in CTRL (a), or SF conditions
(b), or under 24 hours 1% O2 preconditioning, in either CTRL (c), or SF conditions (d). (F): Apoptosis analysis by Annexin V and PI of hAFS
under 24 hours: (a) 20% O2 CTRL and (b) 20% O2 SF conditions, (c) 1% O2 CTRL and (d) 1% O2 SF conditions. Abbreviations: CD, cluster of dif-
ferentiation; hAFS, human amniotic fluid stem cells; HIF-1a, hypoxia inducible factor-1 alpha; HLA, human leucocyte antigen; n.d., not deter-
mined; PI, propidium iodide; SF, serum-free.
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Gene expression levels were normalized to GAPDH (HDF) and
B2M (C2C12) as endogenous controls using the 2-ddCt method. For
more details, refer to Supporting Information.
Statistical Analysis
Results are presented as mean6 SEM of at least three (n 5 3)
independent experiments. Analyses were performed using Graph-
Pad Prism Version 6.0a (GraphPad Software); p values< .05 were
considered statistically significant. For more details, refer to Sup-
porting Information.
RESULTS
Hypoxic Preconditioning Does Not Significantly
Alter hAFS Stemness
To enrich the hAFS secretome with EV, cells were subject to a 24-
hour preconditioning in SF medium under normoxic (20% O2) or
hypoxic conditions (1% O2), the latter of which has been shown to
enhance secretion of EV from stem cells [9, 27–29]. hAFS were
analyzed under the following conditions: (a) control normoxic
(20% O2 in complete medium, CTRL); (b) SF normoxic (20% O2 in
SF medium, SF); (c) control hypoxic (1% O2 in complete medium,
CTRL), and (d) SF hypoxic (1% O2 in SF medium, SF). hAFS did not
show any substantial morphological alteration under hypoxic ver-
sus normoxic conditions, both in CTRL and SF culture (Fig. 1A).
Also, the expression of the stem markers SSEA4 and NANOG
(Fig. 1A) was not significantly altered. SSEA4 was consistently
expressed by more than 83% of hAFS, regardless of the culture
settings (Fig. 1C). While NANOG mRNA was not significantly
affected by preconditioning (Fig. 1D), protein expression was het-
erogeneously distributed in hAFS, yet without any evident differ-
ence compared to the control condition (Fig. 1A). HIF-1a
expression confirmed that 24-hours treatment was sufficient for
the hAFS to become responsive to the hypoxic microenvironment
(Fig. 1B). hAFS immunophenotype remained unaltered, lacking
expression for hematopoietic and mature lineage antigens—such
as CD45, CD34, human leucocyte antigen (HLA) Class II, and
CD31—and showing reasonably high to medium-high expression
of the canonical mesenchymal markers CD73, CD90, CD44, and
CD105. A small, but non-significant decrease in CD73 and CD105
expression was detected in hypoxic and SF conditions. hAFS cells
showed variable CD146 expression, as previously reported [30,
31], while they maintained robust expression of HLA Class I (Fig.
1E; Supporting Information Table S1). hAFS viability was variable:
although the SF condition affected hAFS more than hypoxic
stimulation, this was not statistically significant and likely depend-
ent on hAFS donor variation (Fig. 1F; Supporting Information Table
S1).
hAFS Secrete EV in Their Conditioned Medium
TEM analysis revealed that hAFS can actively secrete EV ranging in
size from 50 to 1,000 nm (Fig. 2A). We further investigated hAFS-
EV secretion for 24 hours under SF conditions to avoid any con-
tamination by Fetal Bovine Serum (FBS)-EV (1% O2 hypoxic versus
20% O2 normoxic) [5]. The hAFS-CM ultracentrifuged pellet con-
tained hAFS-EV between 50 and 200 nm (Fig. 2B), thus including
both exosomes and microvesicles [5]. The vesicle electron density
and the absence of nuclear or cytoplasmic residues in both the EV
released in situ by the cells (Fig. 2A), and the hAFS-EV isolated by
ultracentrifugation (Fig. 2B), demonstrated that apoptotic bodies
were not significantly present. Nanoparticle tracking (Fig. 2C)
showed a reasonably high number of particle in both hAFS-
EVNormo and hAFS-EVHypo (283.336 64.75 3 10
6 particle/ml and
283.836 79.85 3 106 particle/ml, respectively, p 5 .65). Both
hAFS-EVNormo and hAFS-EVHypo particle dimension showed aver-
age size of 180 nm, likely due to clustering effects previously
described for other progenitor-derived EV [32]. BCA assay was
performed to evaluate the protein content on the EV surface.
Hypoxic preconditioning led to a significant enrichment of pro-
teins on the hAFS-EV surface (4.196 0.43 lg/106 cells) with
almost twofold increase compared to normoxic cells (2.356 0.26
lg/106 cells, Fig. 2D, ***p< .001). WB confirmed the expression
of the microvesicle and exosome canonical markers TSG101 and
ALIX [5] on the hAFS-EV (Fig. 2E). Notably, hAFS-EV did not express
GRP94, indicating no contamination from the endoplasmic reticu-
lum associated with apoptotic blebs [33] (Fig. 2E). FACS analysis
revealed a significant exosomal subpopulation expressing the
markers CD81, CD9, AnnV [5, 34], and CD63 [5] within the hAFS-
EV (Fig. 2F and Supporting Information Fig. S2B). In particular,
hypoxic preconditioning led to a significant enrichment of CD811,
CD91, and CD631 exosomes in hAFS-EVHypo compared to the
hAFS-EVNormo (1.5-, 1.3-, and 2.4-fold, *p< .05 and **p< .01,
respectively), despite similar total secreted particle content. We
also labeled hAFS-EV using the CellTrace Far Red DDAO-SE kit to
distinguish intact vesicles from cell debris, as recently described
by others [35]. CellTrace-positive hAFS-EV were further analyzed
for the expression of the MSC antigen CD105, showing that
approximately 60% of them maintained this marker [17] (61.3%6
2.3% and 59.4%6 12.3% in hAFS-EVNormo and hAFS-EVHypo,
respectively, p 5 .8985, Supporting Information Fig. S2A). hAFS-EV
did not express costimulatory molecules CD80 and CD86 [36], sug-
gesting immune tolerance (Supporting Information Fig. S2B).
Figure 2. hAFS secrete EV containing microvesicles and exosomes. (A): Transmission electron microscopy (TEM) analysis of hAFS under 24
hours 20% O2 CTRL (a) or 20% O2 SF conditions (b) and 1% O2 CTRL (c) or 1% O2 SF (d) conditions; scale bars 500 nm. (B): TEM Analysis of 1%
O2 hAFS-EV (hAFS-EVHypo); scale bar 500 nm in (d
0); 200 nm in (d0 0); and 100 nm (d0 0 0 and d0 0 0 0). (C): Nanosight analysis measuring the amount
of particles within hAFS-EVNormo (283.36 64.8 3 10
6 particle/ml) and hAFS-EVHypo (283.86 79.9 3 10
6 particle/ml) released by 106 cells
(right panel); values are expressed as mean6 SEM. Representative images of the graphical output are reported in the left panel. (D): BCA
assay of the protein concentration of hAFS-EVHypo (4.26 0.4 lg/10
6 cells, ***, p< .001, p 5 .0005) over hAFS-EVNormo (2.46 0.3 lg/10
6 cells)
released by 106 cells. (E): Western Blot analysis of TSG101, ALIX, GRP94, and bACTIN by hAFS and hAFS-EV, both under 20% O2 and 1% O2 SF
conditions. (F): FACS analysis of hAFS-EVNormo and hAFS-EVHypo bound to the ExoCap
TM Capture Beads compared to control empty beads
(CTRL BEADS) for the exosomal markers CD81 (*, p< .05, p 5 .049; **, p< .01, p 5 .005; ***, p< .001, p 5 .0004), CD9 (*p< .05, p 5 .047;
**, p< .01, p 5 .0015; ***, p< .001, p 5 .0002), and CD63 (*, p< .05, p 5 .02; **, p< .01, p 5 .004; ***, p< .001, p 5 .0002). Representa-
tive dot plots are illustrated in the left panel, the evaluation of the MFI ratio on the right panels. Abbreviations: CD, cluster of differentiation;
EV, extracellular vesicles; hAFS, human amniotic fluid stem cells; Hypo, hypoxic; MFI, mean fluorescent intensity; Normo, normoxic; SF,
serum-free.
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Analysis of hAFS-EV Biological Effects on Target Cells
The role of both hAFS-EVHypo and hAFS-EVNormo as biological
mediators of paracrine effects was assessed on different target
cells.
Analyses on HDF, C2C12, and hPBMC incubated for 3 hours
with either PKH671 hAFS-EVNormo or hAFS-EVHypo showed similar
internalization efficiency (65.4%6 4.4% and 63.5%6 5.6%
PKH671HDF, p 5 .94; 75.9%6 3.4% and 83.7%6 1.1% PKH671
C2C12, p 5 .11, and 9.3%6 2.6% and 12.5%6 2.5% PKH671
hPBMC, p 5 .54, respectively, Fig. 3A). Following 4 hours incuba-
tion with 1 lg/104, 2 lg/104, and 4 lg/104 cells hAFS-EVNormo,
proliferation of BrDU-labeled HDF showed a dose-dependent, 2-
to almost 3.5-fold increase, compared to untreated cells
(****p< .0001). hAFS-EVHypo treatment further stimulated HDF
proliferation by 2.5- to 4.3-fold change compared to untreated
cells (****p< .0001), and with higher dose-effect response com-
pared to hAFS-EVNomro (
##p< .01; #p< .5, and ###p< .001, Fig. 3B;
Supporting Information Table S2). C2C12 mouse myoblast cell line
underwent oxidative stress by treatment with 1 mM H2O2 for 2
hours in the presence of hAFS-EV. MTT analysis showed that cells
exposed to H2O2 had 65% lower cell viability (****p< .0001). Fol-
lowing 3 hours of pretreatment with hAFS-EV, C2C12 cells signifi-
cantly recovered from injury, with improved cell viability and
increased proliferation (Fig. 3C). hAFS-EVNormo mediated remark-
able dose-dependent antiapoptotic effects enhancing cell survival
up to two- and sixfold compared to control cells and to cells not
receiving any treatment before undergoing oxidative stress,
respectively (****p< .0001). hAFS-EVHypo exerted an even more
effective cytoprotective role by increasing cell viability in a dose-
dependent manner up to 3- and eightfold (Fig. 3C; Supporting
Information Table S2, ****p< .0001). Moreover, the prosurvival
influence exerted by hAFS-EVHypo was significantly more effective
than that observed with hAFS-EVNormo (
####p< .0001).
To understand the immunomodulatory potential of hAFS-EV,
hPBMC were stimulated by PHA [25] and PWM [26] in order to
activate T- and B-lymphocytes, followed by incubation with either
hAFS-EVNormo or hAFS-EVHypo. The target cell response was eval-
uated by analyzing cell proliferation and selective maturation into
T reg and memory B cells by the expression of CD4/CD25 (high)
[37] and CD19/CD27 [38], respectively. hAFS-EV were internalized
by hPBMC with lower efficiency compared to other target cells
used in this study (Fig. 3A). Both hAFS-EVNormo and hAFS-EVHypo
did not significantly affect hPBMC proliferation in control
Figure 4. hAFS-EV exert a certain degree of angiogenic potential in
a mouse Matrigel plug assay. (A): Representative images of Matrigel
plugs loaded with 10 lg of hAFS-EVNormo or hAFS-EVHypo and recov-
ered after 3 weeks from C57Bl/6J mice; scale bar 5 mm. (B): Evalua-
tion of blood hemoglobin content on the Matrigel plugs loaded
with 10 lg of hAFS-EVNormo or hAFS-EVHypo versus the PBS control
*, p< .05 (p 5 .04). (C): Real time qRT-PCR analysis on the recov-
ered plugs for Cdh5, VegfA, and Pecam1 expression as normalized to
B2M expression. (D): Representative images of histological evalua-
tion of vessel formation within the Matrigel plug by infiltrating host
cells via hematoxylin and eosin and CD31 staining, scale bar: 50 mm.
CTRL: vehicle loaded (PBS) Matrigel plug; hAFS-EVNormo: hAFS-
EVNormo loaded Matrigel plug; hAFS-EVHypo: hAFS-EVHypo loaded
Matrigel plug. Abbreviations: CD, cluster of differentiation; EV,
extracellular vesicles; hAFS, human amniotic fluid stem cells; Hypo,
hypoxic; Normo, normoxic.
Figure 3. hAFS-EV mediate paracrine effects on target cells. (A): PKH671 hAFS-EV uptake by HDF, C2C12, and hPBMC by FACS (values nor-
malized to mode on the y-axis) and immunostaining (scale bar: 20 mm). PKH671 cells after treatment with hAFS-EVNormo and hAFS-EVHypo
were: 65.4%6 4.4% and 63.5%6 5.6% HDF (**, p< .01, p 5 .0033 and p 5 .0036, respectively); 75.9%6 3.4% and 83.7%6 1.1% C2C12
(****, p< .0001); 9.3%6 2.6% and 12.5%6 2.5% hPBMC (*, p< .05, p 5 .017). (B): BrdU Enzyme-Linked ImmunoSorbent Assay (ELISA) on
HDF treated with 1 mg/104, 2 mg/104, and 4 mg/104 cells of hAFS-EVNormo and hAFS-EVHypo versus untreated cells (CTRL); ****, p< .0001;
#, p
referring to hAFS-EVHypo versus hAFS-EVNormo:
#, p< .05 (p 5 .033); ##, p< .01 (p 5 .0077); ###, p< .001 (p 5 .0002). Values expressed as the
fold change of sample absorbance read at 370 nm (reference wavelength approximately 492 nm). (C): MTT assay on C2C12 primed with 1
mg/104, 2 mg/104, and 4 mg/104 cells of hAFS-EVNormo or hAFS-EVHypo and exposed to oxidative stress versus untreated cells (CTRL) or dam-
aged cells without hAFS-EV stimulation (H2O2). ****, p< .0001;
#, p referring to hAFS-EVHypo versus hAFS-EVNormo:
####, p< .0001. Values
expressed as the fold change of the sample absorbance read at 560 and 670 nm. (D): hPBMC proliferation under unstimulated (Naive) and
activating (PHA or PWM) conditions with 1 lg/105 cells of hAFS-EVNormo and hAFS-EVHypo versus untreated cells (CTRL hPBMC); CPS. (E):
FACS analysis of mature CD191CD271 B cells treated with 1 lg/105 cells of hAFS-EVNormo or hAFS-EVHypo. Naive hPBMC: 3.48%6 0.86%;
CTRL hPBMC1 PWM: 8.48%6 2.63%; hPBMC1 PWM1 hAFS-EVNormo: 2.32%6 0.96%; hPBMC1 PWM1 hAFS-EVHypo: 2.36%6 0.62%. *,
p< .05 (p 5 .045 and p 5 .047). Abbreviations: CD, cluster of differentiation; CPS, counts per second; DAPI, 40,6-diamidino-2-phenylindole;
EV, extracellular vesicles; hAFS, human amniotic fluid stem cells; HDF, human dermal fibroblast; hPBMC, human peripheral blood mononu-
clear cell; Hypo, hypoxic; MVB, multivesicular body; Normo, normoxic; PHA, phytohemagglutinin; PWM, pokeweed mitogen; SF, serum-free.
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conditions (na€ıve hPBMC, p 5 .6417), or after stimulation (PHA
and PWM, p 5 .3632 and p 5 .5120, Fig. 3D; Supporting Informa-
tion Table S2). hAFS-EV did not influence the polarization of T reg
(Supporting Information Fig. S3A, p 5 .4616). However, both
hAFS-EVNormo and hAFS-EVHypo exerted significant modulatory
effect by reducing the maturation of CD271CD191 memory B cell
in response to PWM (*p< .05, Fig. 3E).
A mouse Matrigel plug assay was used to determine the
proangiogenic effect of hAFS-EVNormo and hAFS-EVHypo in vivo. His-
tological analysis and CD31 immunostaining revealed that in the
hAFS-EV-loaded Matrigel plugs infiltrating host cells were detecta-
ble (Fig. 4A, 4D). Real time qRT-PCR analysis suggested a certain
degree of angiogenic potential of hAFS-EV compared to vehicle-
loaded (PBS) control plugs, as shown by upregulation of the vascu-
lar marker Cdh5, Pecam1, and VegfA on the cells colonizing the
plug (Fig. 4C), although not in a significant manner. Nevertheless,
the evaluation of hemoglobin content showed a 2.6-fold increase
in the hAFS-EVHypo-treated plugs (33.736 7.97 lg/ll) compared
to the control (13.066 1.04 lg/ll, *p< .05) and the hAFS-
EVNormo ones (14.636 1.79 lg/ll, Fig. 4B). Hence, hAFS-EVHypo
were able to, at least to some extent, attract and stimulate host
endothelial cells.
Regenerative Paracrine Potential of hAFS-EV in a Mouse
Model of Skeletal Muscle Atrophy
TA muscle fibers of HSA-Cre, SmnF7/F7 mice treated with hAFS-
EVNormo and hAFS-EVHypo showed remarkable decrease of immu-
noglobulin (IgG) and CD681 cell infiltration compared to control
animals, 1 and 7 days after injection (Fig. 5B). This effect corre-
lated with a drastic reduction of damaged infiltrated fibers
(approximately 80% and 89% in the first 24 hours after hAFS-
EVNormo and hAFS-EVHypo administration, *p< .05, Fig. 5C). In
mice treated with hAFS-EVHypo, this effect was maintained up to 7
days after injection by a 79% decrease of the IgG-damaged fibers
(*p< .05, Fig. 5C). This trend was further confirmed by the evalua-
tion of the percentage of the infiltrated fiber mean fluorescent
area. Indeed, hAFS-EVNormo and hAFS-EVHypo treatments were
equally effective in reducing the extension of the IgG-infiltrated
area within the muscle fibers by 91.5% and 95%, respectively
(**p< .01) at day 1 post injection, and by 80.25% and 91% at day
7 post injection (**p< .01, Fig. 5C). Compared to controls, the
number of central nucleated TA fibers was significantly reduced by
72% 1 day after receiving intramuscular injection of hAFS-EVHypo
(*p< .05, Fig. 5D). This effect was no longer observed after 7
days, although hAFS-EVHypo maintained a significant lower amount
of central nucleated fibers compared to hAFS-EVNormo (71% less,
#p< .05, Fig. 5D). Real time qRT-PCR of the ratio between the
inflammatory markers Nos2 and Arg1 [39] showed a substantial
decrease in the activation of proinflammatory M1 macrophages
(ratio Nos2/Arg1>1), in favor of pro-resolving M2 phenotype
(ratio Nos2/Arg1<1). After 1 day, both hAFS-EVNormo and hAFS-
EVHypo induced macrophage polarization by decreasing the Nos2/
Arg1 ratio by approximately fourfold compared to untreated ani-
mals (*p< .05, Fig. 5E). This effect began to decrease 7 days after
hAFS-EV injection. Proinflammatory cytokines followed a similar
pattern of expression. Following hAFS-EV injection, the expression
of the proinflammatory Il-1a [40] decreased by almost 50% at 1
day (***p< .001) and 7 days (*p< .05) after treatment, with simi-
lar effects between hAFS-EVNormo and hAFS-EVHypo (Fig. 5F). Like-
wise, Il-6 [41] levels dropped significantly by 87% and 65%
(***p< .001 and **p< .01, respectively) within the first 24 hours
after hAFS-EV administration. hAFS-EVHypo was more effective
(*p< .05) as maintaining this modulation for up to 7 days after
treatment (Supporting Information Fig. S4A). Proinflammatory Il-4
[42] expression decreased by 37% 1 day after hAFS-EVHypo treat-
ment (*p< .05). At the same time, within the first 24 hours after
treatment, there was a significant upregulation of the pro-
resolving Il-10, typically released by M2 macrophages [43] (1.6-
fold, **p< .01 and 2.8-fold, ****p< .0001, respectively) with
hypoxic EV exerting a stronger effect compared to normoxic ones
(1.8-fold increase, ****p< .0001, Fig. 5F). This trend was main-
tained also after a few days, although without reaching statistical
significance. hAFS-EV were also able to modulate the expression
of the Pstg2 gene, encoding for the COX2 enzyme, in host cells.
hAFS-EVNormo and the hAFS-EVHypo induced a significant down reg-
ulation of Pstg2 in mice 1 day (67% and 56%, respectively,
**p< .01 and *p< .05), and 7 days (86% and 87%, respectively,
****p< .0001, Supporting Information Fig. S4A) after treatment.
MicroRNA Profiling of the hAFS-EV
hAFS-EVNormo and hAFS-EVHypo showed to contain small non-
coding RNAs and miRNAs (20–40 nucleotides, Fig. 6A). In particu-
lar, hAFS-EVHypo showed significant enrichment over the hAFS-
EVNormo of the following miRNAs (Fig. 6B): miR-223 (***p< .001,
1.3-fold), miR-146a (**p< .01, 1.6-fold), miR-let7c (***p< .001,
twofold), miR-21 (***p< .001, twofold), miR-126 (****p< .0001,
2.5-fold), miR-146b (****p< .0001, almost threefold), miR-199a-
3p (**p< .01, almost threefold), miR-210 (****p< .0001, 3.6-
fold).
Mechanism Insights of the hAFS-EV Regenerative
Potential via Direct Transfer of Exosomal miRNAs Into
the Target Cells
To assess whether direct transfer of their nucleic acid cargo could
drive the hAFS-EV paracrine effect, we analyzed the uptake of
fluorescently labeled exosomal RNA by target cells in vitro.
Figure 5. hAFS-EV decrease muscle inflammation in a mouse model of muscle atrophy. (A): In vivo procedure. (B): IgG (red), CD68 (red), and
LAMININ (green) expression in the Tibialis Anterior muscle of untreated (CTRL) and 1 lg hAFS-EVNormo- and hAFS-EVHypo-treated mice at 1 and 7
days post injection (p.i.); scale bar: 100 lm and 50 lm, respectively. (C): IgG-infiltrated fibers at 1 and 7 days p.i. (CTRL 1 Day: 14.9%6 3.9%;
hAFS-EVNormo 1 Day: 2.9%6 1.4%; hAFS-EVHypo 1 Day: 1.6%6 0.7%; *, p< .05 p 5 .031 and p 5 .016; CTRL 7 Days: 16.1%6 4.3%; hAFS-EVNormo
7 Days: 3.8%6 1.0%; hAFS-EVHypo 7 Days: 2.0%6 0.7%; *, p< .05, p 5 .035) and corresponding mean fluorescent area (CTRL 1 Day: 8.33%6
3.0%; hAFS-EVNormo 1 Day: 0.71%6 0.11%; hAFS-EVHypo 1 Day: 0.42%6 0.1%; **, p< .01, p 5 .002; CTRL 7 Days: 8.90%6 3.2%; hAFS-EVNormo 7
Days: 1.64%6 0.44%; hAFS-EVHypo 7 Days: 0.80%6 0.15%; **, p< .01, p 5 .006 and p 5 .003). (D): Central nucleated fibers at 1 and 7 days p.i.:
CTRL 1 Day: 9.4%6 1.6%; hAFS-EVNormo 1 Day: 4.0%6 1.3%; hAFS-EVHypo 1 Day: 2.6%6 1.3%, *, p< .05, p 5 .015; CTRL 7 Days: 9.8%6 1.7%;
hAFS-EVNormo 7 Days: 13.1%6 3.5%; hAFS-EVHypo 7 Days: 3.7%6 0.9%;
#, p< .05, p 5 .033, as hAFS-EVHypo versus hAFS-EVNormo. (E): Ratio of
Nos2 over Arg2 by real time qRT-PCR; *, p< .05, p 5 .045 and p 5 .036 for hAFS-EVNormo and hAFS-EVHypo;. A.U. (F): Real time qRT-PCR for Il-1a
(***, p< .001, p 5 .0002 and p 5 .001; *, p< .05, p 5 .046 and p 5 .0163, for hAFS-EVNormo and hAFS-EVHypo) and Il-10 (****, p< .0001, **,
p< .01, p 5 .004). Abbreviations: A.U. arbitrary units; CD, cluster of differentiation; DAPI, 40,6-diamidino-2-phenylindole; EV, extracellular vesicles;
hAFS, human amniotic fluid stem cells; Hypo, hypoxic; Normo, normoxic; SF, serum-free.
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RNASelect1 hAFS-EVHypo, we observed acquisition of fluo-
rescence by 88.67%6 4.21% and 86.73%6 4.46% of HDF cells
(****p< .0001 compared to untreated cells), and by 91.5%6
3.38% and 85.97%6 5.51% of C2C12 cells (****p< .0001 com-
pared to untreated ones), respectively (Fig. 6C). This result
indicates that hAFS-EV can actively release their RNA content into
the target cells in the very short time. Real time qRT-PCR analysis
on the responder HDF and C2C12 cells revealed significant enrich-
ment of some of the eight regenerative miRNAs carried by hAFS-
EV (Fig. 6D, 6E). Following incubation with hAFS-EVHypo, HDF cells
showed a significant enrichment of four out of the eight miRNAs
analyzed (Fig. 6D): miR-146a (3.5-fold, **p< .01), miR-126 (4.6-
fold, *p< .05), miR-199a-3p (5.2-fold, *p< .05) and miR-210 (5.1-
fold, *p< .05); all remaining miRNAs (miR-223, miR-let7c, miR-21,
miR-146b) were enhanced in the cells primed with the hAFS-EV,
although this increase was not significant (Supporting Information
Fig. S5A). C2C12 cells primed with the hAFS-EVHypo and exposed
to H2O2, when compared to untreated cells, with or without oxi-
dative damage, revealed higher amount of miR-let7c (3.4- and
2.0-fold, **p< .01 and *p< .05, respectively), miR-21 (4.7-and
6.0-fold, **p< .01), miR-146b (2.6- and 2.9-fold, *p< .05), miR-
199a-3p (2.7- and 3.0-fold, *p< .05 and **p< .01), and miR-210
(7.0- and 3.5-fold, **p< .01 and *p< .05, respectively). Similar to
HDF, all other miRNAs (miR-223, miR-146a, miR-126) were
enhanced in the cells primed with the hAFS-EV, although this
increase was not significant (Supporting Information Fig. S5B).
Since miR-210 was one of the mostly enriched miRNA following
hAFS-EVHypo uptake, we evaluated whether its target genes were
modulated. Expression of MNT, an antagonist of the cell-cycle pro-
moter c-MYC [44], and Casp8ap2, a proapoptotic gene [45], was
analyzed in HDF and C2C12 cells, respectively, following treatment
with hAFS-EVHypo. While HDF cells reduced MNT expression by
almost 60%, this decrease was not statistically significant. On the
other hand, C2C12 cells were able to significantly decrease Cas-
p8ap2 expression of approximately 83% (*p< .05, Supporting
Information Fig. S5C), altogether supporting a substantial, func-
tional role of the transferred miR-210 in mediating antiapoptotic
effect.
Proteomic Profiling of the hAFS-EV
The proteomic characterization of both hAFS-EVNormo and hAFS-
EVHypo allowed the identification of 498 proteins, some of which
(74 out of 100) among those most expressed by exosomes,
according to ExoCarta (http://www.exocarta.org, a dedicated
database of exosomal proteins, RNA and lipids [46]). Eighty-four
proteins out of the total 498 were enriched within the hAFS-
EVHypo compared to the hAFS-EVNormo and significantly involved in
biological pathways (****p< .0001, Supporting Information
Fig. S6A) including metabolism of protein and RNA, including
mRNA, gene expression and translation, metabolism and peptide
chain elongation.
DISCUSSION
Recently, different studies have provided significant insights into
stem cell paracrine-mediated repair as a new strategy for tissue
regeneration [2]. In addition to soluble molecules, cell-released EV
are emerging as potential candidates for future therapeutic
approaches for a number of pathological conditions. Indeed, they
have been demonstrated to play a pivotal role in the intercellular
crosstalk underlying stem cell paracrine potential through the pro-
motion of proliferation, survival, angiogenesis, and immunosup-
pression, just to name a few [47–49].
Here, for the first time, we provide robust evidence that hAFS
dynamically secrete EV as functional mediators of proliferative,
antiapoptotic, immunomodulatory, proangiogenic, and anti-
inflammatory effects.
Structural analyses revealed that hAFS actively release immu-
nologically inert EV, as similarly indicated for other MSC-EV [50],
which are heterogeneous in size. These include nanosized exoso-
mal particles identified by the expression of TSG101, ALIX, CD81,
CD9, AnnV, and CD63 [5, 34], along with cell specific markers such
as CD105. Similar to other stem cells [51], hAFS are likely to origi-
nate from a hypoxic niche within the amniotic fluid, and they
demonstrated remarkable antiapoptotic effects when trans-
planted in an ischemia/reperfusion injury rat model [19]. There-
fore, we applied an in vitro 24 hours hypoxic preconditioning to
enrich the cell secretome with regenerative EV. Consistent with
previous observations on MSC-EV [9, 27, 52], we observed that
hypoxia stimulation did not alter hAFS phenotype or stemness, as
confirmed by NANOG and SSEA4 expression, and it significantly
enriched the exosomal fraction within the hAFS-EV, whereby the
total amount of secreted particles found in hAFS-EVNormo and
hAFS-EVHypo were comparable. hAFS promptly reacted to the
hypoxic environment by upregulating HIF-1a, which has been pre-
viously associated to exosome release in both cardiomyocytes and
cancer cells [52, 53].
Uptake analysis confirmed the role of hAFS-EV as biological
mediators of intercellular communication via rapid incorporation
by the target cells. hAFS-EVHypo in particular showed superior
paracrine influence in mediating both proliferative and prosurvival
effects against oxidative stress on human fibroblasts and murine
Figure 6. hAFS-EV act as biological carrier of regenerative miRNAs which are significantly increased in the target cells following direct
uptake. (A): Analysis of hAFS-EV small non-coding RNA content by Agilent technology. (B): Real time qRT-PCR of hAFS-EVHypo versus hAFS-
EVNormo showing significant enrichment of the following regenerative miRNAs: miR-223 (***, p< .001, p 5 .0001), miR-146a (**, p< .01,
p 5 .009), miR-let7c (***, p< .001, p 5 .0002), miR-21 (***, p< .001, p 5 .0003), miR-199a-3p (**, p< .01, p 5 .002), miR-126, miR-146b,
and miR-210 (****, p< .0001). (C): Uptake analysis of hAFS-EV fluorescently labeled RNA by HDF (upper panel) and C2C12 (lower panel) via
FACS (on the left representative histogram graphs with corresponding values in the graphs on the right). 88.67%6 4.21% and 86.73%6
4.46% of HDF (****, p< .0001) and 91.5%6 3.38% and 85.97%6 5.51% of C2C12 cells (****, p< .0001) became fluorescent following incu-
bation with 1 mg/104 cells of SYTOVR RNASelect1 hAFS-EVNormo and hAFS-EVHypo, showing direct uptake of the marked RNA cargo. (D): Real
time qRT-PCR analysis for the enrichment of specific hAFS-EV-delivered miRNAs in the target proliferative HDF: miRNA-146a, **, p< .01,
p 5 .006; miRNA-126 and miR-199a-3p (*, p< .05, p 5 .03), miR-210 (*, p< .05, p 5 .04). (E): Real time qRT-PCR analysis for the enrichment
of specific hAFS-EV-delivered miRNAs in the target C2C12 with or without H2O2 treatment: miR-let7c (**, p< .01, p 5 .005 and *, p< .05,
p 5 .04); miR-21 (**, p< .01, p 5 .002 and p 5 .001, respectively); miRNA-146b (*, p< .05, p 5 .020 and p 5 .012); miRNA-199a-3p (*,
p< .05, p 5 .013 and **, p< .01 p 5 .008); and miRNA-210 (**, p< .01, p 5 .006 and *, p< .05 p 5 .02). Gene expression was normalized to
human GAPDH and to mouse B2M as internal controls in the HDF and C2C12 cells, respectively. Abbreviations: EV, extracellular vesicles; FITC,
fluorescein isothiocyanate; hAFS, human amniotic fluid stem cells; HDF, human dermal fibroblast; Hypo, hypoxic; Normo, normoxic.
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myoblast cells, compared to hAFS-EVNormo. Our results are coher-
ent with previous findings, which reported that following stimula-
tion with hypoxic CM from human amniotic fluid-derived MSC,
improvement in wound healing was described to occur via the
enhancement of fibroblast activation [54]. Data presented herein
on the antiapoptotic effect during oxidative stress integrate and
support our earlier results on the prosurvival potential of the
hAFS-CM [19] and endorse the idea that the hAFS secretome is a
valuable source of cytoprotective factors. Nevertheless, those pre-
vious findings relied on indirect mechanisms based on soluble
chemokines, cytokines and/or growth factors as the main players
of therapeutic effects: here we report that EV may be another
strategic component of their paracrine potential.
Since mild hypoxic priming was shown to sustain hAFS endo-
thelial regenerative potential in rescuing blood flow in a rodent
model of chronic hind-limb ischemia and carotid injury [18], here
we evaluated if hAFS-EV could induce an angiogenic response in a
Matrigel plug assay in vivo. Despite the fact that differences
among control and hAFS-EV treated groups were not significant in
terms of expression of the angiogenic genes Cdh5, Pecam1, and
VegfA from the host cells colonizing the plug, a positive trend was
noticeable. Nonetheless, hAFS-EVHypo demonstrated a substantial
potential in triggering the maturation of new resident vessels as
revealed by the evaluation of the blood hemoglobin content
within the treated plugs. While the angiogenic potential of stem
cell-EV has been broadly investigated in vitro by several groups
using capillary-forming assay or proliferation of HUVEC [9, 32, 55]
or other endothelial cells [27], at present very little has been
reported using an in vivo Matrigel plug assay, with a rare excep-
tion [56]. In our settings, hAFS-EVHypo showed some degree of
angiogenic potential, which might have been limited by dosage.
Indeed, the only study reporting robust vascular potential of MSC-
EV in a Matrigel plug assay, used a much higher dose of EV (100
lg per plug, 10 times more than that used herein) [56]. Moreover,
we cannot exclude that the angiogenic potential of the hAFS
secretome may reside within the soluble factor content (i.e., the
whole of CM) rather than in the secreted vesicles.
Considering that MSC are well known for their immunomodu-
latory properties, we also investigated whether EV alone can reca-
pitulate the paracrine potential exerted by hAFS in inhibiting the
proliferation of allogeneic human PBMC and lymphocyte activa-
tion [25, 57, 58]. hAFS-EV did not affect proliferation of human
PBMC under resting or challenged conditions and showed to be
up taken with lower efficiency compared to other target cells.
Moreover, we could not detect any alteration in the maturation of
CD41CD25high regulatory T reg by the hAFS-EV. However, both
normoxic and hypoxic hAFS-EV equally mediated a significant
reduction in B-cell maturation. The immunomodulation compe-
tence of MSC-CM in regulating T cell proliferation is well estab-
lished as extensively reviewed in [59, 60]. However, the potential
of EV to recapitulate this feature is still debatable, since a general
consensus has not been reached. Several reports have shown that
MSC-EV can induce tolerogenic signaling by inhibiting syngeneic
and allogeneic T lymphocyte proliferation, while supporting T reg
expansion [61, 62] and attenuating infiltration of neutrophils in a
cardiac ischemia/reperfusion mouse model [7], or by enhancing
the survival of allogeneic skin graft in mice [63]. Yet, other studies
revealed that MSC-EV possess a lower immune-modulatory effect
on T cells in vitro compared to their cellular counterpart [64],
while, on the other hand, they mediate significant immunosup-
pressive effects on memory B cell maturation [65]. Of note, an
independent study has recently shown that the immunoregula-
tory properties of hAFS vary according to gestational age, with
first trimester hAFS exerting stronger inhibitory effects on acti-
vated T-cell proliferation than less effective second and third tri-
mester cells, which need to be primed with specific inflammatory
stimuli Tumor Necrosis Factor-alpha; Interferon-gamma (TNF-a,
INF-g) to block B cell proliferation [57]. Hence, further investiga-
tions on hAFS-EV based on gestational age could help better
understanding these mechanisms. As well, we cannot exclude
whether increasing the hAFS-EV dosage could also provide a sub-
stantial effect on both hPBMC proliferation and T reg activation,
besides effectively targeting B cells.
Our in vitro findings were further validated in vivo in a preclin-
ical model of skeletal muscle atrophy. HSA-Cre, SmnF7/F7 mice
have the exon 7 in the Smn deleted only in skeletal myofibers
with Cre recombinase under the promoter of the human skeletal
actin gene (HSA-Cre). These mice have a high content of central
nucleated fibers, leading to necrosis and infiltration of inflamma-
tory cells, muscle degeneration, and impaired satellite cell poten-
tial [66]. Since systemic administration of murine AFS in HSA-Cre,
SmnF7/F7 mice showed to enhance muscle strength, and support
long-term regeneration following injury [22], here we evaluated
whether hAFS-EV have a paracrine role in this disease model.
Adult bone marrow MSC-derived exosomes recently showed
to promote tissue regeneration by sustaining local angiogenesis
and myogenesis in a skeletal muscle cardiotoxin injury model [67];
here, for the first time, we report that fetal hAFS-EV were effective
in quenching muscle inflammation in a chronic inflammatory envi-
ronment with genetic background. In some cases, hAFS-EVHypo
were more efficient than normoxic EV. Indeed hAFS-EV reduced
the extension of immunoglobulin infiltration within the muscle
fibers, hence counteracting the development of necrotic fibers
and modulated the expression of inflammatory (Il-1a, Il-6, Il-4)
and pro-resolving (Il-10) cytokines. Similarly, the exhaustion of the
resident stem resources caused by the prolonged pathological
activation of the satellite niche was considerably counteracted
within the first 24 hours from treatment with a reduced amount
of central nucleated fibers. Notably, hAFS-EV were also able to
modulate the expression of the Ptgs2 gene encoding for the
proinflammatory enzyme COX2, which has been linked to muscle
wasting and represents a potential therapeutic target for skeletal
muscle atrophy [68]. This is in line with the results of a previous
study showing that rat AFS injected in a model of necrotizing
enterocolitis exerted specific paracrine potential by acting on the
host COX2-expressing stromal cells [21]. However, some of the
beneficial effects revealed here, such balanced levels between
proinflammatory M1 and pro-resolving M2 phenotype and the
modulation of some interleukins were reduced after 7 days. These
findings are in accordance with a general consensus that stem cell
paracrine effect is usually a prompt and short-term response.
Moreover, in our mouse model of genetically induced muscle
atrophy both hAFS-EVHypo and hAFS-EVNormo were equally effec-
tive in delivering most of the regenerative paracrine effects
described. Yet, we report a significantly greater ability of hAFS-
EVHypo to modulate the inflammatory cytokines, Il-10, Il-4, and Il-
6, when compared to hAFS-EVNormo. In light of these considera-
tions, further evaluation is needed to determine whether either
more frequent or higher-dose administration of hAFS-EVHypo can
boost their paracrine potential and maintain it over time.
Recent reports have highlighted the specific role of stem cell-
EV as functional cargo for the horizontal transfer of genetic
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information, such as mRNAs and small non-coding RNAs, including
miRNAs [69, 70]. We revealed that hAFS-EV are endowed with
regenerative miRNAs supporting several key biological effects,
such as proliferation of fibroblasts and other differentiated cells
(miR-210 [71], miR-199a-3p [72]); angiogenesis (miR-210 [73, 74]
and miR-126 [75, 76, 41], the so called “angio-miRNAs” [77]); inhi-
bition of fibrosis (miR-let7c [78]); cardioprotection (miR-210 [32,
79], miR-146a [32, 80]), and prosurvival effect via the activation of
the ERK1/2-Stat3 antiapoptotic signaling pathway (miR-21 [79]);
pro-resolving activity by decreasing the levels of proinflammatory
proteins like RANTES (miR-146b [81]) or PDCD4 (miR-21 [82, 83])
and macrophage polarization toward a pro-resolving, M2 pheno-
type (miR-223 [84]). Coherent with our results on the paracrine
effects elicited by hAFS-EVHypo, hypoxic preconditioning led to a
significant enrichment of miR-210 (a consistent feature of hypoxia
stimulation [85]), miR-199a-3p, miR-146b, miR-126, miR-21, and
miR-let7c.
Considering that miRNA cargo is a distinctive feature of exo-
somes, this evidence further strengthens the hypothesis that
hypoxic preconditioning might represent an ideal strategy to sig-
nificantly enrich hAFS-EV with regenerative exosomes.
Since the results of our comparative proteomic did not iden-
tify any exclusive paracrine candidate molecule, we focused on
the in vitro analysis of miRNA horizontal transfer into the target
cells, to provide some mechanistic insights on the regenerative
effects mediated by the hAFS-EV. Indeed, we verified direct RNA
trafficking from hAFS-EV to responder cells via the labeling of
C2C12 and HDF incorporating the fluorescently marked exosomal
RNA cargo. Additionally, target cells showed significant, higher
enrichment of some of the eight regenerative miRNAs mostly
expressed by hypoxic hAFS-EV. In particular, miR-210 and miR-
199a-3p, in association with others differentially enriched within
C2C12 (miR-let7c, miR-21, and miR-146b) or HDF (miR-146a and
miR-126), were significantly and promptly enhanced following
uptake of hAFS-EVHypo over hAFS-EVNormo.While we cannot ignore
a distinct function of each miRNA in contributing to the beneficial
paracrine effects mediated by the hAFS-EV, we may have identi-
fied a putative regenerative signature with miR-210 and miR-
199a-3p pair. Indeed, the functional role of hypoxic miR-210 in
mediating hAFS-EVHypo-driven prosurvival effects was reinforced
by a significant decrease of expression of its target gene Casp8ap2
in the responder C2C12 cells.
Therefore, we identified a candidate mechanism of action
underlying hAFS-EV paracrine effects by the specific transfer of
hypoxic-stimulated miRNAs. Further experiments, which are
beyond the scope of this initial characterization, are needed to
fully elucidate the specific role of single or combination of hAFS-
EVHypo miRNAs in addressing the different beneficial effects
described here.
CONCLUSION
While functional analyses of microvesicles and exosomes secreted
by both adult and perinatal stem cells (such as placental [48],
amniotic [86, 87], and Wharton’s jelly [88] MSC), have been
reported, little is known about hAFS-EV. To the best of our knowl-
edge this is the first study that provides an initial description of
the paracrine potential of second trimester c-KIT1 hAFS-EV by the
horizontal transfer of specific miRNAs.
Although there are some aspects that need additional atten-
tion to make the EV dose-effect response more efficient in vivo
and to harness the full potential of the hAFS-EVHypo, we believe
that our results still offer meaningful insights on the characteriza-
tion of the fetal stem cell secretome for future therapy.
In order to progress toward the clinical application and to
exploit next generation stem cell-EV therapy, the ideal stem cell
source should be selected upon consideration of their paracrine
potential and the feasibility of their isolation, together with their
in vitro self-renewal properties. hAFS unambiguously fulfill all cri-
teria, since they can be easily isolated from left over samples of
amniotic fluid, either during pregnancy via amniocentesis (fetal
hAFS) or at term, during scheduled cesarean delivery as waste
clinical material (perinatal hAFS). Their remarkable self-renewal
potential, along with the lack of ethical concern, ease of isolation,
expansion, and cryopreservation, make them an optimal candi-
date over adult MSC, iPS, and embryonic stem cells as source for
future paracrine therapy.
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